Mahdi Shahriari1, Saeid Dehghankhalili2, Alireza Heiran3, Babak Daneshfard4. 1. Hematology Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. 3. Non-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Traditional Medicine Clinical Trial Research Center, Shahed University, Tehran, Iran.
Acute lymphoblastic leukemia (ALL) is the most frequent cancer in the under-15-yr-old children accounts for one-third of childhood cancers (1). Individual studies and large consortia, such as the Childhood Leukemia International Consortium (CLIC), are exploring a constellation of factors related to the perinatal origins of the disease (2).An initial investigation on the association between disease incidence and ABO blood group was summarized by Robert in the middle of the 20th century (3). Since then, numerous studies were conducted to focus on the same idea, and within the past several decades, this association was confirmed in some cancers (4, 5). The idea has been supported by multiple systematic reviews and meta-analyses (6, 7); however, it appears that rhesus group system has rarely been deliberated.In a recently conducted clinical investigation in our referral center for childhood cancer (8), we encountered some significant incidental data. In that study, there were forty patients with ALL and except one of them, all were blood Rh negative.In a report by Radhakrishnan et al (9), the authors presented two leukemicpatients with blood group change during their treatment. The mechanism by which the blood group changed in leukemicpatients was not clearly described, but they hypothesized that through epigenetic modifications on the transcription regulating regions of ABO gene in RBCs, malignant cells inhibit the transcription antigens, consequently altering the blood group.More than 80% of Iranian people have Rh positive blood group (10). Hence, we suggested that rhesus antigen D might have a similar situation in ALL patients. Additionally, a polymorphism mechanism might be coupled with such phenomenon (4). Furthermore, it could be possible that rhesus antigen D negative has some potency in conducing ALL, accounting as a risk factor. On the other hand, if this antigen plays a role in the progression of the disease, the immune system might suppress the presentation of this antigen on the red blood cells through epigenetic or other mechanisms.To find out a rigorous scientific explanation and its exact mechanism, more experimental molecular, in vitro and in vivo, studies are warranted.
Authors: Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller Journal: Eur J Cancer Date: 2009-02-21 Impact factor: 9.162
Authors: Eleni Th Petridou; Marios K Georgakis; Friederike Erdmann; Xiaomei Ma; Julia E Heck; Anssi Auvinen; Beth A Mueller; Logan G Spector; Eve Roman; Catherine Metayer; Corrado Magnani; Maria S Pombo-de-Oliveira; Sameera Ezzat; Michael E Scheurer; Ana Maria Mora; John D Dockerty; Johnni Hansen; Alice Y Kang; Rong Wang; David R Doody; Eleanor Kane; Waffa M Rashed; Nick Dessypris; Joachim Schüz; Claire Infante-Rivard; Alkistis Skalkidou Journal: Eur J Epidemiol Date: 2018-05-14 Impact factor: 8.082